The importance of bactericidal drugs: Future directions in infectious disease

被引:132
作者
Finberg, RW
Moellering, RC
Tally, FP
Craig, WA
Pankey, GA
Dellinger, EP
West, MA
Joshi, M
Linden, PK
Rolston, KV
Rotschafer, JC
Rybak, MJ
机构
[1] Univ Massachusetts, Med Ctr, Worcester, MA 01655 USA
[2] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[3] Cubist Pharmaceut, Lexington, MA USA
[4] Univ Wisconsin, Madison, WI 53706 USA
[5] Alton Ochsner Med Fdn & Ochsner Clin, New Orleans, LA 70121 USA
[6] Univ Washington, Seattle, WA 98195 USA
[7] Northwestern Univ, Sch Med, Chicago, IL USA
[8] Univ Maryland, Med Ctr, Baltimore, MD 21201 USA
[9] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA
[10] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[11] Univ Minnesota, Minneapolis, MN USA
[12] Wayne State Univ, Detroit, MI 48202 USA
关键词
D O I
10.1086/425009
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Although a considerable amount of research has gone into the study of the role of bactericidal versus bacteriostatic antimicrobial agents in the treatment of different infectious diseases, there is no accepted standard of practice. Methods. A panel of infectious diseases specialists reviewed the available literature to try to define specific recommendations for clinical practice. Results. In infections of the central nervous system, the rapidity with which the organism is killed may be an important determinant, because of the serious damage that may occur during these clinical situations. The failure of bacteriostatic antibiotics to adequately treat endocarditis is well documented, both in human studies and in animal models. Conclusion. The bulk of the evidence supports the concept that, in treating endocarditis and meningitis, it is important to use antibacterial agents with in vitro bactericidal activity. This conclusion is based on both human and animal data. The data to support bactericidal drugs' superiority to bacteriostatic drugs do not exist for most other clinical situations, and animal models do not support this concept in some situations. Clinicians should be aware that drugs that are bacteriostatic for one organism may in fact be bactericidal for another organism or another strain of the same organism.
引用
收藏
页码:1314 / 1320
页数:7
相关论文
共 83 条
[1]   Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations [J].
Akins, RL ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (02) :454-459
[2]   Randomised comparison of ceftazidime and imipenem as initial monotherapy for febrile episodes in neutropenic cancer patients [J].
Aparicio, J ;
Oltra, A ;
Llorca, C ;
Montalar, J ;
Herranz, C ;
GomezCodina, J ;
Pastor, M ;
Munarriz, B .
EUROPEAN JOURNAL OF CANCER, 1996, 32A (10) :1739-1743
[3]   EXPERIMENTAL ENDOCARDITIS DUE TO PSEUDOMONAS-AERUGINOSA .2. THERAPY WITH CARBENICILLIN AND GENTAMICIN [J].
ARCHER, G ;
FEKETY, FR .
JOURNAL OF INFECTIOUS DISEASES, 1977, 136 (03) :327-335
[4]   STUDY OF BACTERICIDAL AND BACTERIOSTATIC ANTIBIOTICS IN ANIMALS WITH NORMAL AND SUPPRESSED IMMUNITY [J].
BIRO, L ;
IVAN, E .
CHEMOTHERAPY, 1968, 13 (02) :100-&
[6]  
BODEY GP, 1972, CANCER-AM CANCER SOC, V29, P1697, DOI 10.1002/1097-0142(197206)29:6<1697::AID-CNCR2820290638>3.0.CO
[7]  
2-K
[8]   Prospective randomized study to compare imipenem 1.5 grams per day vs. 3.0 grams per day in infections of granulocytopenic patients [J].
Böhme, A ;
Shah, PM ;
Stille, W ;
Hoelzer, D .
JOURNAL OF INFECTION, 1998, 36 (01) :35-42
[9]   MECHANISM OF ACTION OF SPIRAMYCIN AND OTHER MACROLIDES [J].
BRISSONNOEL, A ;
TRIEUCUOT, P ;
COURVALIN, P .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1988, 22 :13-23
[10]   Time-dependent antibacterial effects of linezolid in experimental rabbit endocarditis [J].
Buchanan, LV ;
Dailey, CF ;
LeMay, RJ ;
Zielinski, RJ ;
Kuo, MST ;
Gibson, JK .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (03) :440-441